Archive: "Dutch Peptide Symposium 2016"

Biosynth Carbosynth Expands Peptide Offering with Acquisition of Pepscan

Joshua Valentin News releases

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.  Staad, 30 June 2022 – Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services. Biosynth’s ability to deliver chemical manufacturing services “from the first idea to the finished product” is now matched in peptides, with Pepscan’s expertise in both …

Pepscan’s personalized neoantigen peptide pools in phase I trial “PneoVCA with Pembro in Advanced Solid Tumors”

Joshua Valentin News releases

Lelystad, the Netherlands, June 28, 2022 – Pepscan, the all-in-one peptide service provider, is excited to announce that it will supply personalized peptide pools for six patients in a phase I trial led by Mayo Clinic principal investigator Yanyan Lou, M.D., Ph.D., in collaboration with Keith L. Knutson, Ph.D. The trial tests the safety and tolerability of an experimental personalized peptide vaccine when given in combination with pembrolizumab in treating patients with a wide range of advanced solid tumors and …

All-in-one peptide service provider Pepscan viert 25-jarig bestaan

Joshua Valentin News releases

Lelystad, Nederland, … 25 juni 2022 – Pepscan toast op het 25-jarig bestaan. Als spin-off van de Wageningen Universiteit is de organisatie inmiddels uitgegroeid tot een wereldwijd toonaangevende peptide-expert, die innovatieve biofarmaceutische bedrijven bedient met peptide-diensten en -producten. Van ‘discovery’ tot peptide-leveringen voor klinische studies met patiënten. Pepscan grijpt het jubileum aan om de prestaties te delen met de buitenwereld, te beginnen met de familieleden van medewerkers. Voor de meeste voorbijgangers op de Zuidersluisweg in Lelystad is Pepscan een onopvallend …

How epitope mapping at Pepscan became a way to identify a disease’s Achilles’ heel

Joshua Valentin News releases

Hans Langedijk on dedication and persistence in scientific research “First, we need to understand a disease before we can take the step towards discovery and development of a treatment. To gain functional understanding of the disease mechanisms of pathogens, such as viruses, a lot of data is needed. And that’s exactly what the Pepscan epitope mapping method has to offer,” says Hans Langedijk, former Senior Scientist and Project Leader at Pepscan. After receiving his master’s degree in Chemistry from the …

Pepscan continues to supply personalized peptide pools for Evaxion’s upcoming phase IIb trial after successful completion of phase I/IIa

Juul Zwinkels News releases

Pepscan, the all-in-one peptide service provider with proprietary constraining technologies, is excited to announce that its specialists will manufacture the personalized peptide pools for the treatment of cancer patients in Evaxion’s phase IIb trial. Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, recently published the initial results of the peptide-based personalized therapy EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal …

How continuous improvement resulted in unique peptide library technology

Juul Zwinkels News releases

Wim Schaaper (PhD) on early improvement engineering “Which opportunities do we see that would further improve our peptide library technology and make it even more effective? This was a returning topic on the Pepscan agenda and for me personally a very nice challenge to work on,” says Wim Schaaper, Senior Scientist at Pepscan from 2001 till his retirement in 2017. Currently Pepscan has, as many companies, a team of improvement engineers. Wim Schaaper is considered the companies’ first improvement engineer, …

Pepscan announces research collaboration with Fusion Pharmaceuticals to discover and develop peptide-based radiopharmaceuticals

Juul Zwinkels News releases

Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced a strategic research collaboration with Fusion Pharmaceuticals to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Pepscan’s unique CLIPS™ phage display platform will screen billions of peptides to discover highly constrained de novo peptides with enhanced affinities, selectivities, and proteolytic stabilities. “We are pleased to partner with Pepscan, a global leader in peptide discovery with a platform that will enable us to create novel, …

Column purification technology expanded to guarantee short timelines and flexibility for (GMP) batches

Juul Zwinkels News releases

At Pepscan, we help you guide your peptide project through the various stages of development towards clinical application and commercialization. To support the growing number of customers looking for mid-sized batches of custom-made (GMP) peptides, Pepscan has extended our column purification technology with a mid-sized column packer. “This technology significantly reduces purification time compared to the methodology for smaller batch sizes,” explains Richard van Duinkerken, Purified Peptides team lead. “This new equipment ensures that we can keep providing our clients …

How the first effective peptide vaccine was developed at Pepscan

Juul Zwinkels News releases

Jan Langeveld (PhD) on how luck, international collaboration and “pur sang” research led to success. In 1990, Jan Langeveld joined forces with Rob Meloen, who later became Pepscan’s founder but at the time was working for the Institute for Animal Science and Health in Lelystad. For Langeveld, the Pepscan technique seemed a quick and cheap way to unravel antibody specificity, and represented a revolution in our understanding of protein structure and function. At the time, Meloen was also expecting progress …

How mastering peptides became Pepscan’s DNA

Juul Zwinkels News releases

Rob Meloen on how ingenuity and dedication became the core of Pepscan “The power of Pepscan has always been the people: incredibly smart, dedicated and ingenious. Not only in finding scientific solutions but also in operational areas. I believe it says it all that I used to say, ‘No more discoveries after Friday 3 o’clock’,” shares Rob Meloen, founder of Pepscan, with a smile on his face. “To develop new vaccines, therapeutics or diagnostic tools, you have to put a …

We use cookies to ensure that we give you the best experience on our website. If you would like to, you can change your cookie settings in your browser.
For more information check our privacy policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies